FreeCME


Released on August 1, 2019

Expires on August 1, 2020

Media Type: Internet

Specialty: Dermatology, Primary Care, Internal Medicine

This program consists of 2 modules. Module 1, Disease Overview & Patient Considerations in Psoriasis, provides a summary of the symptoms, complications, and emotional impact of psoriasis, along with a series of short videos showing interactions between a standardized patient with psoriasis and their healthcare provider to showcase the importance of shared decision-making. Module 2, Psoriasis Treatment & Patient Perspectives, provides education and updates on the currently available and emerging therapeutic options, strategies for creating an individualized treatment plan, and the importance of the multidisciplinary team. Module 2 also includes an interview with a psoriasis patient advocate. Also available are a series of clinical and patient support tools.

 

 

 

 

Co-provided by Purdue College of Pharmacy and Integrity Continuing Education, Inc.

This activity was supported by an educational grant from Celgene Corporation. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Available

  • Module 1: Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)
  • Module 2: Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational initiative has been designed for dermatologists, nurse practitioners, and physician assistants involved in the management of patients with psoriasis.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement a multidisciplinary approach to the care of patients with psoriasis in order to effectively manage the underlying disease and associated comorbidities
  • Assess recent findings in the medical literature regarding FDA-approved therapies for psoriasis, along with safety and efficacy data on novel therapies undergoing late-stage clinical trials
  • Illustrate the importance of patient-centered care on addressing burdens associated with psoriasis

Faculty

April W. Armstrong, MD, MPH
Professor of Dermatology
Associate Dean of Clinical Research
Director, Psoriasis Program
University of Southern California
Los Angeles, California

Accreditation Statement

Purdue College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Purdue College of Pharmacy designates this enduring material (Module 1) for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Purdue College of Pharmacy designates this enduring material (Module 2) for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Purdue College of Pharmacy requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Purdue College of Pharmacy for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

April W. Armstrong, MD, MPH

  • Consulting Fees: AbbVie, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen Pharmaceuticals, Leo Pharma, Modernizing Medicine, Novartis, Ortho
  • Contracted Research: AbbVie, Bristol-Myers Squibb, Dermira, Eli Lilly, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Leo Pharma, Novartis, Regeneron Pharmaceuticals

The Purdue College of Pharmacy and Integrity Continuing Education, Inc. planners have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Purdue College of Pharmacy, Integrity Continuing Education, Inc., Celgene Corporation, Janssen Biotech, Inc., and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 1, 2019 through August 1, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better for Module 1, and a completed activity evaluation form and a completed posttest with a score of 80% or better for Module 2.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

For information about the accreditation of this program, please contact the Purdue University College of Pharmacy at pharmacy-cecr@purdue.edu.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.